Assessing the genomic feature of Chinese patients with ampullary adenocarcinoma: potential therapeutic targets.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Duodenal Neoplasms* ; Pancreatic Neoplasms* ; Adenocarcinoma*/drug therapy ; Adenocarcinoma*/genetics ; Common Bile Duct Neoplasms*; Humans ; B7-H1 Antigen ; Phosphatidylinositol 3-Kinases ; Genomics ; China/epidemiology
    • Abstract:
      Backgrounds: Ampullary adenocarcinoma (AMPAC) is a rare malignancy, treated as pancreatic or intestinal cancer based on its histologic subtype. Little is known about the genomic features of Chinese patients with AMPAC.
      Materials and Methods: We enrolled 145 Chinese AMPAC patients in our local cohort and performed a compressive somatic and germline genetic testing using a 156 gene panel. Expression of PD-L1 (clone 28 - 8) was also assessed in tumor specimens from 64 patients.
      Results: The frequency of genetic alterations (GAs) in Chinese patients with AMPAC was found to be distinctive, with TP53, KRAS, SMAD4, APC, CTNNB1, ARID1A, and CDKN2A emerged as the most frequently mutated genes. Comparing with Western patients, significant differences were observed in the prevalence of PIK3CA and ARID2. Furthermore, the incidence of MSI-H was lower in the Chinese cohort, with only two patients identified as MSI-H. Conversely, 11 patients (8.27%) had pathogenic/likely pathogenic germline alterations, all of which were in the DNA damage response (DDR) pathway. In our cohort, 34.48% (22/64) of patients exhibited positive PD-L1 expression in tumor cells, and this expression was associated with GAs in CTNNB1 and BLM. Importantly, over three-fourths of Chinese AMPAC patients in our study had at least one actionable GA, with more than one-fifth of them having actionable GAs classified as Level 3. These actionable GAs were primarily involved in the DDR and PI3K pathways. Notably, GAs in the DDR pathway were detected in both Chinese and Western patients, and regardless of their functional impact, these alterations demonstrated enhanced overall survival rates and higher tumor mutational burden (TMB) levels.
      Conclusion: These findings underscore the distinct genomic landscape of Chinese AMPAC patients and highlight the potential for targeted therapies based on the identified GAs.
      (© 2024. The Author(s).)
    • References:
      Lancet Oncol. 2020 Apr;21(4):508-518. (PMID: 32135080)
      Oncogene. 2021 Jan;40(4):863-874. (PMID: 33262464)
      JCO Precis Oncol. 2017 Jul;2017:. (PMID: 28890946)
      Am J Surg Pathol. 2014 Oct;38(10):1371-9. (PMID: 24832159)
      Genome Med. 2017 Apr 19;9(1):34. (PMID: 28420421)
      Cell Rep. 2016 Feb 2;14(4):907-919. (PMID: 26804919)
      Clin Colorectal Cancer. 2022 Sep;21(3):236-243. (PMID: 35450836)
      Front Immunol. 2021 Oct 28;12:759565. (PMID: 34777372)
      Cancer Genet. 2021 Nov;258-259:41-48. (PMID: 34455261)
      Nature. 2012 Nov 15;491(7424):399-405. (PMID: 23103869)
      J Clin Invest. 2018 Oct 1;128(10):4441-4453. (PMID: 30179225)
      Nat Med. 2020 Dec;26(12):1859-1864. (PMID: 33020649)
      Cancer Cell. 2016 Feb 8;29(2):229-40. (PMID: 26806338)
      J Immunother Cancer. 2020 Dec;8(2):. (PMID: 33268350)
      J Clin Invest. 2019 May 21;129(8):3264-3276. (PMID: 31112530)
      Am J Surg Pathol. 2012 Nov;36(11):1592-608. (PMID: 23026934)
      Science. 2018 Feb 16;359(6377):770-775. (PMID: 29301958)
      J Natl Compr Canc Netw. 2023 Jul;21(7):753-782. (PMID: 37433437)
      Ann Oncol. 2020 Jun;31(6):807-814. (PMID: 32171752)
      Cancer Res. 2019 Jul 1;79(13):3163-3168. (PMID: 31196931)
      Minerva Gastroenterol Dietol. 2019 Jun;65(2):85-90. (PMID: 30488680)
      J Clin Pathol. 2020 Oct;73(10):656-664. (PMID: 32591352)
      Cancer. 2020 Nov 1;126(21):4788-4799. (PMID: 32857459)
      Bosn J Basic Med Sci. 2018 Aug 01;18(3):268-274. (PMID: 29131967)
      Nat Commun. 2022 Jun 28;13(1):3724. (PMID: 35764656)
      Ann Oncol. 2018 Sep 1;29(9):1895-1902. (PMID: 30137196)
      Gut. 2014 Feb;63(2):326-36. (PMID: 23946381)
      Surg Oncol. 2022 Sep;44:101841. (PMID: 36087543)
      J Clin Pathol. 2019 Nov;72(11):762-770. (PMID: 31256008)
      Cancer Cell. 2017 Jul 10;32(1):57-70.e3. (PMID: 28648284)
      PLoS Comput Biol. 2016 Apr 21;12(4):e1004873. (PMID: 27100738)
      Cancer Res. 2000 Feb 15;60(4):803-7. (PMID: 10706084)
      Genet Med. 2015 May;17(5):405-24. (PMID: 25741868)
      Mod Pathol. 2016 Dec;29(12):1575-1585. (PMID: 27586202)
      J Mol Diagn. 2017 Jan;19(1):4-23. (PMID: 27993330)
      Histopathology. 2017 Sep;71(3):470-474. (PMID: 28502094)
      Cancer. 2019 May 1;125(9):1441-1448. (PMID: 30620386)
      Gut. 2023 Jul;72(7):1255-1257. (PMID: 37041069)
      Lancet Oncol. 2022 Mar;23(3):e116-e128. (PMID: 35090673)
    • Contributed Indexing:
      Keywords: Actionable alteration; Ampullary adenocarcinoma; DDR; Germline; Somatic
    • Accession Number:
      0 (B7-H1 Antigen)
      EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
    • Publication Date:
      Date Created: 20240304 Date Completed: 20240306 Latest Revision: 20240307
    • Publication Date:
      20240307
    • Accession Number:
      PMC10910796
    • Accession Number:
      10.1186/s12885-024-11949-9
    • Accession Number:
      38439030